Arcus Biosciences Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
RCUS$18.95+3.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In millions, except per share amounts)
| March 31,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $192 | $150 |
| Marketable securities | 805 | 828 |
| Receivable from collaboration partners ($4 and $6 from a related party) | 15 | 20 |
| Prepaid expenses and other current assets | 19 | 18 |
| Total current assets | 1,031 | 1,016 |
| Long-term marketable securities | 8 | 14 |
| Property and equipment, net | 46 | 47 |
| Other noncurrent assets | 71 | 73 |
| Total assets | $1,156 | $1,150 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $22 | $18 |
| Deferred revenue ($72 and $85 to a related party) | 72 | 85 |
| Other current liabilities | 98 | 123 |
| Total current liabilities | 192 | 226 |
| Deferred revenue, noncurrent ($219 and $234 to a related party) | 219 | 234 |
| Long-term debt | 48 | 48 |
| Other noncurrent liabilities | 166 | 157 |
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 105.9 shares in 2025 and 92.2 shares in 2024 issued and outstanding | 1,775 | 1,617 |
| Accumulated deficit | (1,244) | (1,132) |
| Total stockholders’ equity | 531 | 485 |
| Total liabilities and stockholders’ equity | $1,156 | $1,150 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.